Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

NCT07061951 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

NIH

Sponsor class

Conditions

Recurrent Chronic Lymphocytic Leukemia
Recurrent Small Lymphocytic Lymphoma
Refractory Chronic Lymphocytic Leukemia
Refractory Small Lymphocytic Lymphoma

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Marrow Biopsy
PROCEDURE: Computed Tomography
PROCEDURE: Echocardiography Test
DRUG: Mirdametinib

Sponsor

National Cancer Institute (NCI)